These results suggest that the administration of a CXCR4 inhibitor can enhance the cytotoxic activity of tumor‐infiltrated CD8+ T cells induced by ICIs, particularly when administered at a circadian phase during which CD8+ T cells are retained in CAF‐rich regions and segregated from tumor cells within immune‐cold tumor tissues. The gene discussed is CXCR4; the disease is neoplasm.